Matrix Metalloproteinase Inhibitors in Cancer Therapy

  • Neil J. Clendeninn
  • Krzysztof Appelt

Part of the Cancer Drug Discovery and Development book series (CDD&D)

Table of contents

  1. Front Matter
    Pages i-xiii
  2. Mark D. Sternlicht, Lisa M. Coussens, Thiennu H. Vu, Zena Werb
    Pages 1-37
  3. Hideaki Nagase
    Pages 39-66
  4. Barbara Fingleton, Lynn M. Matrisian
    Pages 85-112
  5. Peter D. Brown, Alan H. Davidson, Alan H. Drummond, Andrew Gearing, Mark Whittaker
    Pages 113-142
  6. David R. Shalinsky, Bhasker Shetty, Yazdi Pithavala, Steve Bender, Anthony Neri, Stephanie Webber et al.
    Pages 143-173
  7. G. Clemens, B. Hibner, R. Humphrey, H. Kluender, S. Wilhelm
    Pages 175-192
  8. A. D. Baxter, J. B. Bird, R. Bannister, R. Bhogal, D. T. Manallack, R. W. Watson et al.
    Pages 193-221
  9. Frank Grams, Hans Brandstetter, Richard A. Engh, Dagmar Glitz, Hans-Willi Krell, Valeria Livi et al.
    Pages 223-243
  10. Michael R. Niesman
    Pages 245-254
  11. Back Matter
    Pages 255-262

About this book


The association of matrix metalloproteinases (MMPs)-enzymes that disrupt the body's normal repair functions-with several diseases, including growing and invasive tumors, holds the tantalizing promise that their inhibiton might have therapeutic value. In Matrix Metalloproteinase Inhibitors in Cancer Therapy, cutting-edge investigators review the current status of the entire field, from the biology of MMPs through the current clinical studies. The authors include many leading scientists from pharmaceutical companies who present all the latest concepts and results on the preferred design strategies for MMP inhibitors, their molecular mechanisms, and their substrates. In addition, they fully describe their company's research effort on specific MMP inhibitors, detailing vanguard design strategies, their in vitro activity, the outcome of animal model studies and, where available, their toxicology, safety, and efficacy in human clinical trials. Comprehensive and state-of-the-art, Matrix Metalloproteinase Inhibitors offers basic and clinical investigators alike a richly informative summary of all the latest research on these powerful new drugs, and their high promise as emerging cancer therapeutics.


cancer cancer therapy clinical trial oncology research toxicology

Editors and affiliations

  • Neil J. Clendeninn
    • 1
  • Krzysztof Appelt
    • 2
  1. 1.Corporate V.P., Clinical AffairsAgouron Pharmaceuticals Inc.San DiegoUSA
  2. 2.Department of Research PharmacologyAgouron Pharmaceuticals Inc.San DiegoUSA

Bibliographic information